The Effect of Cord Blood Serum Eyes Drops Administer in Patients With Severe Keratopathy Related to EGFR-I Treatment
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Feb 14, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of eye drops made from cord blood serum on patients who have severe dry eye caused by a specific type of cancer treatment. The main goal is to see if these eye drops can help heal the surface of the eye, known as the corneal epithelium, which can become damaged due to medication used for treating certain cancers.
To join this study, participants need to be adults over 18 years old who have advanced cancer and a specific genetic mutation (EGFr mutation) that requires treatment with anti-EGFr drugs. Participants will need to be able to store and use the eye drops on their own or with help from a caregiver. Those who qualify will be part of a trial that is currently recruiting, and they can expect to contribute to important research that may help improve eye health for others facing similar issues in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age over 18 years
- • oncology and advanced cancer patients who have EGFr mutation and who require treatment with antiEGFr drugs
- • signing of informed consent
- Exclusion Criteria:
- • Patients who are unable to store/administer the CSCO independently, or with the help of care-givers.
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Luigi Fontana, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported